Annex Advisory Services 13F: Adds $42M to Amgen (AMGN) Stake
Annex Advisory Services has boosted its stake in Amgen Inc., now holding over 111,000 shares valued at nearly $47 million.
Reviewed by automated data checks against the source filing. How we make and check alerts
Annex Advisory Services added 98,954 shares to its stake in Amgen Inc. ($AMGN), a 794.24% increase, according to a 13F filing with the SEC dated October 16, 2026. It reported 111,413 shares worth $46.96 million at the end of the quarter.
Find the original: Annex Advisory Services 13F filings on SEC EDGAR
AMGN
Amgen Inc.
Key Points
- Annex Advisory Services boosted its stake in Amgen Inc. by 98,954 shares, raising its total to 111,413 shares valued at about $46.96 million.
- Amgen shares recently traded around $432.06, which is about 4.2% above its 50-day moving average and 17.3% above its 200-day average.
- Analysts have mixed opinions on Amgen, with a consensus target price of $394.98 and a recommendation to hold the stock.
Get $AMGN trade alerts by text
We text you when insiders, Congress or big funds trade $AMGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Amgen Inc. alert may contain errors. Disclosures
Annex Advisory Services has increased its stake in Amgen Inc. (AMGN) as reported in its latest Form 13F filing on October 16, 2026. The firm boosted its holdings by 98,954 shares, bringing its total position to 111,413 shares valued at approximately $46.96 million. This marks a substantial increase of about 794.2%. The filing reflects holdings as of the reporting period and may not represent the investor's current position.
What Changed in Annex Advisory Services' Amgen Position
Annex Advisory Services added 98,954 shares to its existing position in Amgen, boosting its stake from 12,459 to 111,413 shares. The total value of the increased position is about $46.96 million.
Other Institutional Activity in Amgen
Several other funds have also made adjustments to their Amgen holdings. Blackrock Inc. owns 49,362,016 shares valued at around $21.35 billion after increasing its stake by 2,260,856 shares. Vanguard Capital Management LLC holds 35,250,101 shares worth about $15.25 billion, having added 234,604 shares. State Street Corporation has 30,560,537 shares, while Capital World Investors slightly reduced its stake by 213,811 shares, ending with 29,075,329 shares valued at approximately $12.57 billion. Invesco Ltd. grew its position by 435,254 shares, bringing its total to 16,320,446 shares worth about $7.06 billion.
Amgen Inc. Stock Up 1.4%
As of October 16, 2026, Amgen shares traded around $432.06, which is above both its 50-day and 200-day moving averages, indicating a strong upward trend. However, the stock is about 3.3% below its 52-week high of $447.03, suggesting some room for growth. The shares are also 50% above their 52-week low of $288.00.
Recent Earnings
For the trailing twelve months, Amgen reported revenue of approximately $38.09 billion and earnings per share (EPS) of $16.10. The company has shown a revenue growth of 9.5% year-over-year, and it boasts a net margin of 23%. The next earnings report is scheduled for November 3, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 6.1%. Revenue missed estimates by 1.5%.
-
Profit surprise
EBITDA missed by 45 percent. Operating income missed by 28 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
1 target raise, 2 target cuts.
-
Earnings quality
Gross margin up 4.6 points. Operating margin up 16.5 points. Positive free cash flow.
Earnings Call Summary
Amgen had a strong first quarter with earnings per share of 5.15 dollars beating expectations of 4.73 dollars. Six key medicines grew sales by 24 percent year over year and now make up 70 percent of total sales. The obesity drug Meritide is advancing well in late-stage testing with new studies showing better tolerance when patients take it less frequently, potentially every eight to twelve weeks instead of weekly injections.
Guidance Amgen raised its 2026 outlook to revenue between 37.1 billion and 38.5 billion dollars, and earnings per share between 21.70 and 23.10 dollars. The company expects its fast-growing medicines like Repatha and Evenity to offset patent losses. Management said capital spending will remain at about 2.6 billion dollars to scale manufacturing for new drug launches.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Insider Buying and Selling at Amgen Inc.
Several insiders at Amgen have sold shares recently. Nancy A. Grygiel, an officer, sold 2,970 shares on August 6, 2026, at an average price of $402.16 for a total value of about $1.19 million. Derek Miller, also an officer, sold 3,890 shares the same day at $402.54, totaling around $1.57 million. Additionally, Rachna Khosla sold 3,252 shares on August 13, 2026, valued at approximately $1.35 million.
Analysts Set New Price Targets
Analysts have maintained various ratings on Amgen recently. On October 8, 2026, RBC Capital maintained an Outperform rating with a price target of $430. On October 9, 2026, UBS also maintained a Buy rating, raising its target to $470. BMO Capital kept a Market Perform rating with a target of $415, while Wells Fargo maintained an Equal-Weight rating at $430. Guggenheim rated the stock Neutral with a target of $378.
About Amgen
Amgen Inc. is a biotechnology company based in Thousand Oaks, California. It specializes in discovering, developing, and manufacturing human therapeutics. The firm's innovative treatments and therapies play an important role in the healthcare sector, making its stock an interesting watch for investors given the recent institutional activity.
Bottom Line
Looking ahead, investors will be watching Amgen's next earnings report on November 3, 2026. The recent filing by Annex Advisory Services highlights the firm's confidence in Amgen amid a market that is carefully assessing biotech valuations. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.
Related Filing Alerts
Source: Annex Advisory Services's 13F filing on $AMGN (Oct 16, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Annex Advisory Services 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts